Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 2 for:    Bevacizumab-800CW | Breast Cancer
Previous Study | Return to List | Next Study

Fluorescence Guided Surgery in Breast Cancer (MARGIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02583568
Recruitment Status : Completed
First Posted : October 22, 2015
Last Update Posted : February 13, 2017
Martini Hospital Groningen
Information provided by (Responsible Party):
G.M. van Dam, University Medical Center Groningen

Brief Summary:
A need for further investigation for fluorescence image-guided surgery in breast conserving surgery (BCS) has arisen following the results obtained from a phase I feasibility breast cancer trial (BIRDYE study: ABR NL 37479.042011). The aim of this study is to define the optimal dose of the fluorescent tracer Bevacizumab-IRDye800CW for intraoperative delineation of breast cancer tissue using the improved and optimized fluorescent tracer and camera system.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Bevacizumab-800CW Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection Surgery in Patients With Breast Cancer
Study Start Date : October 2015
Actual Primary Completion Date : January 2017
Actual Study Completion Date : February 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Part 1
In part 1 a dose escalation will be performed for the tracer bevacizumab-800CW in four different dose groups (4,5mg 10mg 25mg 50mg)
Drug: Bevacizumab-800CW
three days prior to surgery bevacizumab-800CW will be administered
Other Name: Bevacizumab-IRDye800CW

Experimental: Part 2
In part 2, the two best performing dose groups of bevacizumab-800CW of part 1 will be expanded to a total of 10 patients per group.
Drug: Bevacizumab-800CW
three days prior to surgery bevacizumab-800CW will be administered
Other Name: Bevacizumab-IRDye800CW

Primary Outcome Measures :
  1. Tumor-to-background ratio [ Time Frame: day 3 ]

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events [ Time Frame: up to two weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Main Inclusion Criteria:

  1. Females aged ≥ 18 years.
  2. Confirmed diagnosis of breast cancer by means of histology or cytology and eligible for breast cancer surgery.
  3. Tumor size ≥ 5 mm (0, 5 cm) diameter according to anatomical imaging data.
  4. WHO performance score 0-2.
  5. Life expectancy greater than 12 weeks
  6. Written informed consent has been obtained
  7. In the Investigator's opinion, patient is able and willing to comply with all trial requirements.

    For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal:

  8. A negative serum pregnancy test prior to receiving the second generation tracer
  9. Willing to ensure that she or her partner uses effective contraception during the trial and for 3 months thereafter.

Main Exclusion Criteria:

  1. Medical or psychiatric conditions that compromise the patient's ability to give informed consent
  2. Breast prosthesis in the target breast
  3. History of infusion reactions to Bevacizumab or other monoclonal antibody therapies
  4. Concurrent anticancer therapy (chemotherapy, radiotherapy, vaccines, immunotherapy) delivered within the last 6 weeks prior to the start of the treatment
  5. Significant renal or hepatic impairment.
  6. Inadequately controlled hypertension with or without current antihypertensive medications.
  7. History of myocardial infarction, transient ischemic attack, cerebro vascular accident, pulmonary embolism, uncontrolled congestive heart failure (CHF), significant liver disease, unstable angina within 6 months prior to enrollment.
  8. Patients receiving anticoagulant therapy with vitamin K antagonists.
  9. Patients receiving Class IA (e.g. Quinidine) or Class III (e.g. Dofetilide, Amiodarone, Sotalol) antiarrhythmic agents.
  10. Evidence of QT prolongation on pre-treatment ECG (Males >440 ms, Females >450 ms).
  11. Magnesium, potassium and calcium levels below lower normal limit which is regarded clinically relevant with regards to study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02583568

Layout table for location information
University Medical Center Groningen
Groningen, Netherlands, 9713 GZ
Sponsors and Collaborators
University Medical Center Groningen
Martini Hospital Groningen
Layout table for investigator information
Principal Investigator: G.M van Dam, prof. dr. UMCG
Layout table for additonal information
Responsible Party: G.M. van Dam, prof.dr., University Medical Center Groningen Identifier: NCT02583568    
Other Study ID Numbers: NL52447.042.15
First Posted: October 22, 2015    Key Record Dates
Last Update Posted: February 13, 2017
Last Verified: February 2017
Keywords provided by G.M. van Dam, University Medical Center Groningen:
breast cancer
image-guided surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors